A carregar...
Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury
BACKGROUND AND PURPOSE: Enhanced mammalian target of rapamycin (mTOR) signalling contributes to the pathogenesis of diabetes and plays a critical role in myocardial ischaemia/reperfusion (I/R) injury. Rapatar is a novel nanoformulated micellar of rapamycin, a putative inhibitor of mTOR that has been...
Na minha lista:
| Publicado no: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727242/ https://ncbi.nlm.nih.gov/pubmed/28967097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14059 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|